open access

Vol 14, No 5 (2019)
Review Papers
Get Citation

ISAR-REACT 5: should this trial change clinical practice?

Małgorzata Ostrowska, Piotr Adamski, Jacek Kubica
Folia Cardiologica 2019;14(5):488-492.

open access

Vol 14, No 5 (2019)
Review Papers

Abstract

Prasugrel and ticagrelor are oral P2Y12 receptor inhibitors indicated by the European Society of Cardiology as the preferred antiplatelet therapy in patients with acute coronary syndrome (ACS). Despite the long-term and widespread presence of these agents in clinical practice, to date they have never been directly compared in a large, randomised clinical trial. ISAR-REACT 5 was the first such study, and it reported the superiority of prasugrel over ticagrelor. However, due to the arguable methodology of both the planning and the execution of this study, its results should be interpreted with caution, and they should not be considered sufficient to justify any changes to the current treatment strategies for patients with ACS.

Abstract

Prasugrel and ticagrelor are oral P2Y12 receptor inhibitors indicated by the European Society of Cardiology as the preferred antiplatelet therapy in patients with acute coronary syndrome (ACS). Despite the long-term and widespread presence of these agents in clinical practice, to date they have never been directly compared in a large, randomised clinical trial. ISAR-REACT 5 was the first such study, and it reported the superiority of prasugrel over ticagrelor. However, due to the arguable methodology of both the planning and the execution of this study, its results should be interpreted with caution, and they should not be considered sufficient to justify any changes to the current treatment strategies for patients with ACS.

Get Citation

Keywords

acute coronary syndrome, antiplatelet therapy, prasugrel, ticagrelor

About this article
Title

ISAR-REACT 5: should this trial change clinical practice?

Journal

Folia Cardiologica

Issue

Vol 14, No 5 (2019)

Pages

488-492

Bibliographic record

Folia Cardiologica 2019;14(5):488-492.

Keywords

acute coronary syndrome
antiplatelet therapy
prasugrel
ticagrelor

Authors

Małgorzata Ostrowska
Piotr Adamski
Jacek Kubica

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl